SCYNEXIS Secures $24.8M, Extends Runway and Doses First SCY-247 IV Patient
SCYNEXIS received a one-time $24.8 million payment from GSK in Q4 2025, leaving $56.3 million in cash and a cash runway exceeding two years. SCYNEXIS initiated Phase 1 IV dosing of SCY-247 with topline data due H2 2026 and is planning an expanded access program in H1 2026.
1. Year-End Cash and GSK Payment
SCYNEXIS received a one-time $24.8 million non-refundable payment from GSK in Q4 2025 under a binding memorandum, driving full-year license revenue to $20.6 million. The company closed the period with $56.3 million in cash, cash equivalents and investments, supporting more than two years of operational runway.
2. SCY-247 IV Phase 1 Progress
In late February 2026, SCYNEXIS dosed its first patient with the intravenous formulation of SCY-247 in a Phase 1 study. Topline safety and pharmacokinetic data are expected in the second half of 2026, paving the way for a planned proof-of-concept Phase 2 invasive candidiasis trial later in the year.
3. Expanded Access and Regulatory Designations
Responding to unmet needs, SCYNEXIS plans to launch an expanded access program for SCY-247 in the first half of 2026. The U.S. FDA has granted Qualified Infectious Disease Product and Fast Track designations for SCY-247, expediting its development path.
4. BREXAFEMME NDA Transfer and Milestones
On November 19, 2025, SCYNEXIS completed transfer of the BREXAFEMME NDA to GSK, positioning the partner to relaunch the product. SCYNEXIS stands to earn up to $145.5 million in annual net sales milestones plus low- to mid-single-digit royalties after relaunch.